Patents Represented by Attorney Albert P. Pennie & Edmonds Halluin
  • Patent number: 6100054
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 8, 2000
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Patent number: 5766939
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 16, 1998
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Patent number: 5759828
    Abstract: The present invention provides the nucleotide sequences of Acetobacter operons, cdg operons encoding genes for the biosynthesis and degradation of cyclic diguanosine monophosphate (c-di-GMP). Specifically, the nucleotide sequences and deduced amino acid sequences of 3 phosphodiesterases isozymes, 3 diguanylate cyclase isozymes, and 2 polypeptides of unidentified function are provided. Also provided for are various strains of microorganisms, including Acetobacter cells genetically manipulated so as to produce elevated and/or reduced levels of one or more cdg operon encoded proteins.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: June 2, 1998
    Assignee: Weyerhaeuser
    Inventors: Rony Tal, David H. Gelfand, Roger D. Calhoon, Arie Ben-Bassat, Moshe Benziman, Hing Cheung Wong
  • Patent number: 5716508
    Abstract: The present invention relates to an electrophoresis media comprising a gel and a compound capable of restricting the diffusion of water within the gel. Diffusion restricting compounds useful in the present invention include but are not limited to polyols, polymeric alcohols, polysaccharides, polyoxyethylene ethers, polyamines, polypeptides, gums, zwiterionic detergents and mixtures thereof. The present method relates to any electrophoresis media and includes but is not limited to polyacrylamide, agarose, starch, cellulose acetate and sepharose. A further embodiment of the present invention relates to a stacking gel wherein a diffusion restricting compound is used to prevent diffusion of water between the stack gel and resolving gel. The addition of a diffusion restricting compound to the stacking gel has the particular advantage of causing the stacking gel to become opaque, thereby facilitating the addition of samples to the gel.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: February 10, 1998
    Assignee: Glyko Incorporated
    Inventor: Christopher M. Starr
  • Patent number: 5646019
    Abstract: The present invention relates to an improved method for producing primed nucleic acid templates. Specifically, it relates to a method, compositions and kits therefor, of increasing the specificity of primer extension reactions by hybridizing primer to template in the presence of single-stranded nucleic acid binding protein.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: July 8, 1997
    Assignee: Stratagene
    Inventors: Kirk B. Nielson, Eric J. Mathur
  • Patent number: 5637483
    Abstract: A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: June 10, 1997
    Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins University School of Medicine
    Inventors: Glenn Dranoff, Richard C. Mulligan, Drew Pardoll
  • Patent number: 5637621
    Abstract: The invention provides fungicidal compounds having the general formula:X.sub.1 -A.sub.1 -B.sub.1 -C-B.sub.2 -A.sub.2 -X.sub.2 (I)wherein X.sub.1 is an amidine, a guanidine, or an imidazole group.A.sub.1 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring;B.sub.1 is either O (oxygen) or absent; C is a straight chain alkyl comprising 1-8 carbons; B.sub.2 is either O (oxygen) or absent; A.sub.2 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring; and X.sub.2 is an amidine, a guanidine, or an imidazole.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 10, 1997
    Assignee: NZYM, Inc.
    Inventors: Joel Bolonick, Terrance J. Leighton, Ida K. Yu
  • Patent number: 5631151
    Abstract: The present invention is directed to a process for producing melanins, their precursors and their analogues, hereinafter referred to generically as melanins. According to the invention, melanins are produced in amounts greater than about 3.3 grams wet weight per liter of growth medium. The enhanced production of melanin can be achieved by manipulating the constituents of the growth medium, and/or attenuating fermentations conditions, and/or by genetically engineering microorganisms to produce melanins, and/or mutating the microorganisms.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: May 20, 1997
    Assignee: Biosource Technologies, Inc.
    Inventors: Guy della-Cioppa, Stephen J. Garger, Jr., Genadie G. Sverlow, Thomas H. Turpen, Laurence K. Grill, Miles R. Chedekel, Monto H. Kumagai
  • Patent number: 5629348
    Abstract: The invention provides fungicidal compounds having the general formula:X.sub.1 -A.sub.1 -B.sub.1 -C-B.sub.2 -A.sub.2 -X.sub.2 (I)wherein X.sub.1 is an amidine, a guanidine, or an imidazole group.A.sub.1 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring;B.sub.1 is either O (oxygen) or absent; C is a straight chain alkyl comprising 1-8 carbons; B.sub.2 is either O (oxygen) or absent; A.sub.2 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring; and X.sub.2 is an amidine, a guanidine, or an imidazole.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: May 13, 1997
    Assignee: NZYM, Inc.
    Inventors: Joel Bolonick, Terrance J. Leighton, Ida K. Yu
  • Patent number: 5605824
    Abstract: The present invention relates to an improved composition for hybridizing polynucleotides with complementary nucleic acid sequences. Specifically, it relates to a composition for of increasing the specificity of a polynucleotide hybridization reaction in the presence of single-stranded nucleic acid binding protein.
    Type: Grant
    Filed: June 16, 1993
    Date of Patent: February 25, 1997
    Assignee: Stratagene
    Inventors: Kirk B. Nielson, Eric J. Mathur
  • Patent number: 5593859
    Abstract: The invention is transfected cells, substantially all of which contain at least one human collagen gene and express fibrillar collagen molecules derived using methods for synthesizing collagen and collagen fibrils in said cell lines, and methods for treatment of disorders in humans using said collagen derived from said stable cell lines.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: January 14, 1997
    Assignee: Thomas Jefferson University
    Inventors: Darwin J. Prockop, Leena Ala-Kokko, Andrzej Fertala, Aleksander Sieron, Kari I. Kivirikko, Amy Geddis, Taina Pihlajaniemi
  • Patent number: 5591839
    Abstract: Polynucleotide sequences encoding enzymes that possess .alpha.2-3 neuraminidase activity are provided. Of particular interest are polynucleotide sequences encoding an enzyme having .alpha.2-3 neuraminidase activity and naturally produced by the bacteria Streptococcus pneumoniae. Recombinant DNA expression of enzymes possessing .alpha.2-3 specific neuraminidase activity is also described, including methods, recombinant host cells and a genetic construction. The invention also provides a purified enzyme having .alpha.2-3 neuraminidase activity from Streptococcus pneumoniae, wherein the enzyme is isolated from S. pneumoniea cultures. Another aspect of this invention is to provide methods of isolating genes encoding enzymes having neuraminidase activity, particularly .alpha.2-3 neuraminidase activity. The gene isolation methods of the invention comprise the step of labeling a hybridization probe derived from the neuraminidase coding portion of plasmid pND-1.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: January 7, 1997
    Assignee: Glyko, Inc.
    Inventors: Harvey I. Miller, John C. Klock, Christopher M. Starr
  • Patent number: 5589392
    Abstract: A system for regulating expression of eukaryotic genes in cells is described. The system contains two recombinant DNA molecules, a first molecule that encodes a nucleus-targeted inducible repressor polypeptide, and a second molecule that encodes an operator-regulated reporter polypeptide. Transgenic animals containing the system, and methods for using the system are also described.
    Type: Grant
    Filed: November 29, 1993
    Date of Patent: December 31, 1996
    Assignee: Stratagene
    Inventor: Jay M. Short
  • Patent number: 5589367
    Abstract: The present invention is directed to recombinant plant viral nucleic acids and to hosts infected thereby. The recombinant plant viral nucleic acids comprise a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and optionally, at least one non-native nucleic acid sequence to be transcribed or expressed in the infected host plant. The recombinant plant viral nucleic acids are stable, capable of systemic infection and capable of stable transcription or expression in the plant host of the non-native nucleic acid sequences.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: December 31, 1996
    Assignee: Biosource Technologies, Inc.
    Inventors: Jon Donson, William O. Dawson, George L. Granthan, Thomas H. Turpen, Ann M. Turpen, Stephen J. Garger, Laurence K. Grill
  • Patent number: 5580776
    Abstract: Genetically engineered or transduced hepatocytes which express genetic material of interest introduced or incorporated into them, as well as methods of producing, transplanting and using the genetically engineered hepatocytes. The genetic material of interest can be incorporated through use of a vector, such as a recombinant retrovirus, which contains the genetic material of interest, or by other means.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: December 3, 1996
    Assignees: Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research
    Inventors: James M. Wilson, Richard C. Mulligan
  • Patent number: 5571697
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: November 2, 1994
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine Texas Medical Center
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Patent number: 5571896
    Abstract: The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for human lactoferrin protein. Methods for the production of human lactoferrin protein in A. Oryzae are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant human lactoferrin protein.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Patent number: 5571691
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Patent number: 5545552
    Abstract: Purified thermostable Pyrococcus furiosus DNA polymerase that migrates on a non-denaturing polyacrylamide gel faster than phosphorylase B and Taq polymerase and more slowly than bovine serum albumin and has an estimated molecular weight of 90,000-93,000 daltons when compared with a Taq polymerase standard assigned a molecular weight of 94,000 daltons.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: August 13, 1996
    Assignee: Stratagene
    Inventor: Eric J. Mathur
  • Patent number: 5529909
    Abstract: The present invention relates to a nucleic acid sequence that encodes a fusion enzyme of tyrosinase and a tyrosinase activator protein. Further, the present invention also relates to the amino acid sequence which is encoded by the nucleic acid sequence of the fusion enzyme. The fusion enzyme may also include a linker positioned between the amino acid sequences of the tyrosinase and the tyrosinase activator protein. Still further, the present invention also relates to a vector useful for introducing the nucleic acid sequence encoding the fusion enzyme into an organism. Still further, the present invention relates to melanins made by the fusion enzyme and a method for making melanins using the fusion enzyme.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: June 25, 1996
    Assignee: Biosource Technologies, Inc.
    Inventors: Guy della-Cioppa, Monto Kumagai